Literature DB >> 19222428

Antagonism of non-depolarising neuromuscular block: current practice.

A F Kopman1, M Eikermann.   

Abstract

There is now mounting evidence that even small degrees of postoperative residual neuromuscular block increases the incidence of adverse respiratory events in the Post Anaesthesia Care Unit and may increase longer-term morbidity as well. In the absence of quantitative neuromuscular monitoring, residual block is easily missed. A very strong case can be made for the routine administration of a non-depolarising antagonist unless it can be objectively demonstrated that complete recovery has occurred spontaneously. However, the use of acetylcholinesterase inhibitors is associated with the potential for cardiovascular and respiratory side-effects, so there are cogent reasons for using low doses when the level of neuromuscular block is not intense. As little as 0.015-0.025 mg.kg(-1) of neostigmine is required at a train-of-four count of four with minimal fade, whereas 0.04-0.05 mg.kg(-1) is needed at a train-of-four count of two or three. If only a single twitch or none at all can be evoked, neostigmine should not be expected to promptly reverse neuromuscular block, and antagonism is best delayed till a train-of-four-count of two is achieved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19222428     DOI: 10.1111/j.1365-2044.2008.05867.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  15 in total

1.  Sugammadex: Efficacy and Practicality in the Dental Office.

Authors:  Stephen Goetz; Benjamin Pritts; Bryant Cornelius
Journal:  Anesth Prog       Date:  2018

2.  Evaluation of neostigmine antagonism at different levels of vecuronium-induced neuromuscular blockade in isoflurane anesthetized dogs.

Authors:  Augusto M Lorenzutti; Manuel Martin-Flores; Juan M Baldivieso; Martín A Himelfarb; Nicolás J Litterio
Journal:  Can Vet J       Date:  2014-02       Impact factor: 1.008

3.  Respiratory events with sugammadex vs. neostigmine following laparoscopic sleeve gastrectomy: a prospective pilot study assessing neuromuscular reversal strategies.

Authors:  Shmuel Evron; Yuri Abelansky; Tiberiu Ezri; Alexander Izakson
Journal:  Rom J Anaesth Intensive Care       Date:  2017-10

4.  Neuromuscular Block and Blocking Agents in 2018.

Authors:  Christoph Unterbuchner
Journal:  Turk J Anaesthesiol Reanim       Date:  2018-04-01

5.  Residual Paralysis: Does it Influence Outcome After Ambulatory Surgery?

Authors:  Hassan Farhan; Ingrid Moreno-Duarte; Duncan McLean; Matthias Eikermann
Journal:  Curr Anesthesiol Rep       Date:  2014-12

6.  ROUTINE USE OF SUGAMMADEX DOES NOT SHORTEN PACU LENGTH OF STAY: A PROSPECTIVE DOUBLE-BLINDED RANDOMIZED CONTROLLED TRIAL.

Authors:  Germán Echeverry; Lily Polskin; Luis E Tollinche; Kenneth Seier; Kay See Tan; Patrick J McCormick; Gregory W Fischer; Florence M Grant
Journal:  Perioper Care Oper Room Manag       Date:  2021-07-16

Review 7.  Sugammadex: a review of its use in anaesthetic practice.

Authors:  Lily P H Yang; Susan J Keam
Journal:  Drugs       Date:  2009       Impact factor: 9.546

8.  Comparative Effectiveness of Calabadion and Sugammadex to Reverse Non-depolarizing Neuromuscular-blocking Agents.

Authors:  Friederike Haerter; Jeroen Cedric Peter Simons; Urs Foerster; Ingrid Moreno Duarte; Daniel Diaz-Gil; Shweta Ganapati; Katharina Eikermann-Haerter; Cenk Ayata; Ben Zhang; Manfred Blobner; Lyle Isaacs; Matthias Eikermann
Journal:  Anesthesiology       Date:  2015-12       Impact factor: 7.892

9.  Acetylcholine and an acetylcholinesterase inhibitor neostigmine can aggravate tularemia progress in BALB/c mice.

Authors:  Miroslav Pohanka; Oto Pavlis; Hana Svobodova; Jiri Pikula
Journal:  Interdiscip Toxicol       Date:  2012-03

10.  Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study.

Authors:  Martina Grosse-Sundrup; Justin P Henneman; Warren S Sandberg; Brian T Bateman; Jose Villa Uribe; Nicole Thuy Nguyen; Jesse M Ehrenfeld; Elizabeth A Martinez; Tobias Kurth; Matthias Eikermann
Journal:  BMJ       Date:  2012-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.